Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: A cohort study

Calcified Tissue International

Volumn 86, Issue 5, 2010, Pages 335-342

  Vestergaard, Peter ^a   Schwartz, Kristoffer ^b   Pinholt, Else Marie ^b   Rejnmark, Lars ^a   Mosekilde, Leif ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

Alendronate; Atrial fibrillation; Bisphosphonate; Chronic obstructive pulmonary disease; Etidronate; Raloxifene

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; RALOXIFENE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

AGED; ALENDRONATE; ATRIAL FIBRILLATION; ATRIAL FLUTTER; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; COMORBIDITY; CONFOUNDING FACTORS (EPIDEMIOLOGY); DENMARK; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RALOXIFENE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77953361230     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-010-9349-0     Document Type: Article

References (23)

1. Black D, Delmas P, Eastell R, Reid I, Boonen S, Cauley J et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822
2. Lyles K, Colon-Emeric C, Magaziner J, Adachi J, Pieper C, Mautalen C et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809
3. Abrahamsen B, Eiken P, Brixen K (2009) Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 265:581-592
4. Charlson M, Pompei P, Ales K, MacKenzie C (1987) A method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373-383
5. Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM (2008) Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168:826-831
6. Sorensen H, Christensen S, Mehnert F, Pedersen L, Chapurlat R, Cummings S et al (2008) Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based casecontrol study. BMJ 336:813-816
7. Bunch TJ, Anderson JL, May HT, Muhlestein JB, Horne BD, Crandall BG et al (2009) Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103:824-828
8. Loke Y, Jeevanantham V, Singh S (2009) Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 32:219-228
9. Frost L, Vestergaard P, Mosekilde L (2004) Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 164:1675-1678 (Pubitemid 39037947)
10. Frost L, Vestergaard P (2004) Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med 164:1993-1998
11. Frost L, Hune L, Vestergaard P (2005) Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med 118:489-495 (Pubitemid 40615472)
12. Vestergaard P, Mosekilde L (2003) Hyperthyroidism, bone mineral, and fracture risk-a meta-analysis. Thyroid 13:585-593
13. Tanko LB, Bagger YZ, Christiansen C (2003) Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 73:15-20
14. Vestergaard P, Rejnmark L, Mosekilde L (2009) Hypertension is a risk factor for fractures. Calcif Tissue Int 84:103-111
15. Andersen T, Madsen M, JØrgensen J, Mellemkjær L, Olsen J (1999) The Danish National Hospital Register. Dan Med Bull 46:263-268
16. Mosbech J, JØrgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen T (1995) The Danish National Patient Register: evaluation of data quality [in Danish]. Ugeskr Laeger 157:3741-3745
17. Frost L, Vestergaard P, Mosekilde L, Mortensen L (2005) Trends in incidence and mortality in the hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980-1999. Int J Cardiol 103: 78-84
18. Vestergaard P, Rejnmark L, Mosekilde L (2005) Fracture risk associated with systemic and topical corticosteroids. J Intern Med 257:374-384
19. Vestergaard P, Mosekilde L (2003) Fracture risk associated with smoking-a meta-analysis. J Intern Med 254:572-583 (Pubitemid 37521854)
20. Dimal H, Domej W, Leb G, Lau K (2001) Bone loss in patients with untreated chronic obstructive pulmonary disease is mediated by an increase in bone resorption associated with hypercapnia. J Bone Miner Res 16:2132-2141
21. Forli L, Halse J, Haug E, Bjortuft O, Vatn M, Kofstad J et al (2004) Vitamin D deficiency, bone mineral density and weight in patients with advanced pulmonary disease. J Intern Med 256: 56-62
22. De Laet C, Kanis J, Oden A, Johanson H, Johnell O, Delmas P et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330-1338
23. Hanrahan JP, Grogan DR, Baumgartner RA, Wilson A, Cheng H, Zimetbaum PJ et al (2008) Arrhythmias in patients with chronic obstructive pulmonary disease (COPD): occurrence frequency and the effect of treatment with the inhaled long-acting beta2agonists arformoterol and salmeterol. Medicine (Baltimore) 87:319-328